Referencia número: HY-N0400

Wogonin

25 Cited Publications

Revisión del cliente

Based on 25 publication(s) in Google Scholar

Wogonin is a naturally occurring mono-flavonoid, can inhibit the activity of CDK8 and Wnt, and exhibits anti-inflammatory and anti-tumor effects.

Para uso exclusivo en investigación. No vendemos a pacientes.

Pureza: 99.54%
No. CAS: 632-85-9
Fòrmula: C₁₆H₁₂O₅
Peso molecular:284.26

Almacenamiento:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Wogonin Chemical Structure

No. CAS: 632-85-9

Tamaño

Precio

Stock

Cantidad

Amount: USD 0.00

* Seleccione Cantidad antes de agregar artículos.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Actividad biológica
- Descripciòn
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (25)
Solvente y solubilidad
- In Vitro
- In Vivo
Protocolo
Pureza y Documentación
Referencias
Help & FAQs
Classifications
Bioz

Actividad biológica

Descripciòn

Wogonin is a naturally occurring mono-flavonoid, can inhibit the activity of CDK8 and Wnt, and exhibits anti-inflammatory and anti-tumor effects.

IC₅₀ & Target^[1]

CDK8

CDK9

Ver todos los productos específicos de isoformas CDK :

Ver todos los productos específicos de isoformas Wnt :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	15.8 μM Compound: 1	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 28117202]
A549	IC₅₀	20.1 μM Compound: 1	Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 28987604]
A549	IC₅₀	42.3 μM Compound: Wogonin	Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 31238183]
B16	IC₅₀	26.4 μM Compound: 1	Cytotoxicity in mouse B16 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity in mouse B16 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 28987604]
BV-2	IC₅₀	7.8 μM Compound: Wgn, Wogonin	Inhibition of iNOS-induced NO production in LPS-stimulated mouse BV2 cells after 24 hrs Inhibition of iNOS-induced NO production in LPS-stimulated mouse BV2 cells after 24 hrs	[PMID: 22366656]
CHO	IC₅₀	>350 μM Compound: 4	Displacement of [3H]LSD from human 5HT7 receptor expressed in CHO cells Displacement of [3H]LSD from human 5HT7 receptor expressed in CHO cells	[PMID: 12713409]
DLD-1	IC₅₀	36.87 μM Compound: 3; Wogonin	Antiproliferative activity against human DLD1 cells after 48 hrs by MTT assay Antiproliferative activity against human DLD1 cells after 48 hrs by MTT assay	10.1039/C5MD00163C
HCT-116	IC₅₀	27.3 μM Compound: Wogonin	Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 31238183]
HEK293	IC₅₀	28.1 μM Compound: 31	Anti-inflammatory activity against TNFalpha-induced HEK293 cells assessed as inhibition of NF-kappaB activity pre-indubated for 1 hr followed by TNFalpha treatment measured for 5 hrs by luciferase based assay Anti-inflammatory activity against TNFalpha-induced HEK293 cells assessed as inhibition of NF-kappaB activity pre-indubated for 1 hr followed by TNFalpha treatment measured for 5 hrs by luciferase based assay	[PMID: 37683361]
HepG2	IC₅₀	17.6 μM Compound: Wogonin	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 31238183]
HepG2	IC₅₀	19 μM Compound: 1	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 28117202]
HepG2	IC₅₀	19.5 μM Compound: 1	Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 28987604]
HepG2	IC₅₀	37.89 μM Compound: 3; Wogonin	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	10.1039/C5MD00163C
HepG2 2.2.15	IC₅₀	4 μg/mL Compound: 1	Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as decrease in HBV e antigen secretion after 9 days Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as decrease in HBV e antigen secretion after 9 days	[PMID: 24549242]
HT-29	IC₅₀	39.55 μM Compound: 3; Wogonin	Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay	10.1039/C5MD00163C
HUVEC	IC₅₀	105 μM Compound: 3	Inhibition of trypsin-induced elevation in PAI1 production in HUVEC by ELISA Inhibition of trypsin-induced elevation in PAI1 production in HUVEC by ELISA	[PMID: 9214730]
MCF7	IC₅₀	28 μM Compound: 1	Cytotoxicity in human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity in human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 28987604]
MCF7	IC₅₀	30 nM Compound: 44	Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay	[PMID: 36205223]
MCF7	IC₅₀	30 μM Compound: Wagonin	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay	[PMID: 32707525]
MCF7	IC₅₀	30 μM Compound: Wogonin	Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay	[PMID: 31300317]
MCF7	IC₅₀	30 μM Compound: Wogonin	Antiproliferative activity in human MCF7 cells assessed as cell growth inhibition Antiproliferative activity in human MCF7 cells assessed as cell growth inhibition	[PMID: 34411892]
MCF7	IC₅₀	30 μM Compound: Wogonin	Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay	[PMID: 37229829]
MV4-11	IC₅₀	30.7 μM Compound: Wogonin	Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 31238183]
RAW264.7	IC₅₀	1.07 μM Compound: Wogonin	Inhibition of COX2-mediated PGE2 production in LPS-stimulated mouse RAW264.7 cells by enzyme immunoassay Inhibition of COX2-mediated PGE2 production in LPS-stimulated mouse RAW264.7 cells by enzyme immunoassay	[PMID: 19233646]
RAW264.7	IC₅₀	1.08 μM Compound: Wogonin	Evaluated for inhibition of COX-2 catalyzed PGE-2 production from LPS induced RAW 264.7 cells Evaluated for inhibition of COX-2 catalyzed PGE-2 production from LPS induced RAW 264.7 cells	[PMID: 14980657]
Sf21	IC₅₀	12.3 μM Compound: 22	Inhibition of recombinant human full length C-terminal His6-tagged and N-terminal GST-tagged CDK7/cyclinH/MAT1 expressed in baculovirus Sf21 insect cells after 40 mins in presence of [gamma-32P]ATP by scintillation counting analysis Inhibition of recombinant human full length C-terminal His6-tagged and N-terminal GST-tagged CDK7/cyclinH/MAT1 expressed in baculovirus Sf21 insect cells after 40 mins in presence of [gamma-32P]ATP by scintillation counting analysis	[PMID: 30733087]
Sf9	IC₅₀	190 nM Compound: 22	Inhibition of human recombinant N-terminal GST-tagged CDK9 (2 to 372 residues) expressed in baculovirus infected Sf9 insect cells co-expressing human cyclin T1 (2 to 726 residues) after 40 mins in presence of [gamma-32P]ATP by scintillation counting analy Inhibition of human recombinant N-terminal GST-tagged CDK9 (2 to 372 residues) expressed in baculovirus infected Sf9 insect cells co-expressing human cyclin T1 (2 to 726 residues) after 40 mins in presence of [gamma-32P]ATP by scintillation counting analy	[PMID: 30733087]
Sf9	IC₅₀	190 nM Compound: Wogonin	Inhibition of human recombinant N-terminal GST-tagged CDK9 (2 to 372 residues)/N-terminal GST-tagged cyclin-T1 (2 to 726 residues) expressed in baculovirus infected Sf9 insect cells using peptide as substrate after 40 mins in presence of gamma-[32]P-ATP b Inhibition of human recombinant N-terminal GST-tagged CDK9 (2 to 372 residues)/N-terminal GST-tagged cyclin-T1 (2 to 726 residues) expressed in baculovirus infected Sf9 insect cells using peptide as substrate after 40 mins in presence of gamma-[32]P-ATP b	[PMID: 31238183]
SW1353	IC₅₀	39 μM Compound: 6	Antiinflammatory activity in PMA-stimulated human SW1353 cells assessed as inhibition of NF-kappaB activation Antiinflammatory activity in PMA-stimulated human SW1353 cells assessed as inhibition of NF-kappaB activation	[PMID: 19555121]
SW480	IC₅₀	35.06 μM Compound: 3; Wogonin	Antiproliferative activity against human SW480 cells after 48 hrs by MTT assay Antiproliferative activity against human SW480 cells after 48 hrs by MTT assay	10.1039/C5MD00163C

In Vitro

Wogonin (0-200 μM) exhibits a dose- and time- dependent reduces in cell viability of caco-2, SW1116 and HCT116 cells. Wogonin (10-40 μM) induces G1 phase arrest in HCT-116 cells. Wogonin also supresses Wnt signaling pathway in HCT116 cells. Wogonin interfers in the activity of transcription factor TCF/Lef family. Moreover, Wogonin inhibits β-catenin-mediated transcription through suppressing the activity of CDK8^[1]. Wogonin shows cytotoxic and antiproliferative effects on HeLa cells. Wogonin (90 μM) induces cell cycle arrest at G0-G1 phase, and suppresses the levels of cyclin D1 and Cdk4 markedly in HeLa cells^[2]. Wogonin (1.25, 2.5, 5, 10, 20 μg/ml) suppresses EtOH-induced inflammatory response in RAW264.7 cells^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Wogonin (30, 60 mg/kg) reduces tumor growth of HCT116 cells in a xenograft model^[1]. Wogonin (25, 50, 100 mg/kg) protects against liver injury and pathological characteristics of ALD in mice. Wogonin activates PPAR-γ expression in mice with ALD and EtOH induced RAW264.7 cells^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

No. CAS 632-85-9
Appearance Solid
Peso molecular 284.26
Fòrmula C₁₆H₁₂O₅
Color Light yellow to yellow
SMILES

O=C1C=C(C2=CC=CC=C2)OC3=C(OC)C(O)=CC(O)=C13
Structure Classification
- Flavonoids
- Flavones
- Phenols
- Polyphenols
Initial Source
- Plants
- Labiatae
Envío

Room temperature in continental US; may vary elsewhere.
Almacenamiento

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (25)

All Cell Proliferation/Viability AssayWBFlow CytometryIFRT-PCR

Sort by:

Journal Impact Factor

Pharmacol Res

Cardamonin retards progression of autosomal dominant polycystic kidney disease via inhibiting renal cyst growth and interstitial fibrosis. [Abstract]

2020 May;155:104751. PMID: 32151678
Phytomedicine

Antitumor and resensitizing effects of wogonin in thyroid cancer via PDGFRB-dependent mechanisms. [Abstract]

2026 Jul 25:157:158328. PMID: 42217345
Phytomedicine

Fangchinoline suppresses nasopharyngeal carcinoma progression by inhibiting SQLE to regulate the PI3K/AKT pathway dysregulation. [Abstract]

2025 May:140:156484. PMID: 40090046
Phytomedicine

Wogonin mitigates microglia-mediated synaptic over-pruning and cognitive impairment following epilepsy. [Abstract]

2024 Nov 9:135:156222. PMID: 39547095
Phytomedicine

A systematic pharmacology-based in vivo study to reveal the effective mechanism of Yupingfeng in asthma treatment. [Abstract]

2023 Jun:114:154783. PMID: 37004399
Food Chem

Effects of sun drying combined with baking processes on the flavor quality of Chongqing Tuocha raw tea. [Abstract]

2025 Dec 30:497:146992. PMID: 41285060
Food Chem

Flavonoid-mediated metabolic underpinning quality variation in red bud-sport pear mutants. [Abstract]

2025 May 31:489:144992. PMID: 40466530
Chin Med

The combination of Schisandrin C and Luteolin synergistically attenuates hepatitis B virus infection via repressing HBV replication and promoting cGAS-STING pathway activation in macrophages. [Abstract]

2024 Mar 18;19(1):48. PMID: 38500179
Eur J Pharmacol

Wogonin inhibits oxidative stress and vascular calcification via modulation of heme oxygenase-1. [Abstract]

2023 Nov 5:958:176070. PMID: 37739306
Eur J Pharmacol

Wogonin attenuates the deleterious effects of traumatic brain injury in anesthetized Wistar rats. [Abstract]

2019 Apr 5:848:121-130. PMID: 30689996
Int J Mol Sci

Wogonin Inhibits Apoptosis and Necroptosis Induced by Nephropathogenic Infectious Bronchitis Virus in Chicken Renal Tubular Epithelial Cells. [Abstract]

2024 Jul 27;25(15):8194. PMID: 39125764
Bone Joint Res

Wogonin pretreatment of infrapatellar fat pad mesenchymal stem cell-derived exosomes advances articular cartilage repair in osteoarthritis. [Abstract]

2025 Dec 1;14(12):1064-1079. PMID: 41319983

Wogonin purchased from MedChemExpress. Usage Cited in: Bone Joint Res. 2025 Dec 1;14(12):1064-1079. [Abstract]

Cells were treated with 0, 12.5, 25, or 50 μM Wogonin and examined for cell viability using cell counting kit (CCK)-8 assay.

Wogonin purchased from MedChemExpress. Usage Cited in: Bone Joint Res. 2025 Dec 1;14(12):1064-1079. [Abstract]

Western blot results suggested that MSC^IPFP-Exo and Wogonin-MSC^IPFP-Exo (25 μM) groups showed positive expression of the Exo-specific surface proteins CD81, CD63, and CD9, and negative expression of Calnexin.

Wogonin purchased from MedChemExpress. Usage Cited in: Bone Joint Res. 2025 Dec 1;14(12):1064-1079. [Abstract]

Wogonin (25 μM) treatment enhances the promotion of chondrocyte proliferation and inhibition of apoptosis by MSC^IPFP-Exo.

Wogonin purchased from MedChemExpress. Usage Cited in: Bone Joint Res. 2025 Dec 1;14(12):1064-1079. [Abstract]

Wogonin-MSC^IPFP-Exo (25 μM) suppresses interleukin (IL)-1β-triggered chondrocyte extracellular matrix (ECM) degradation. Chondrocytes were incubated with MSC^IPFP-Exo or Wogonin-MSC^IPFP-Exo in the presence or absence of IL-1β (10 ng/mL) for 24 hours.

Wogonin purchased from MedChemExpress. Usage Cited in: Bone Joint Res. 2025 Dec 1;14(12):1064-1079. [Abstract]

Quantification of Exo biogenesis-related gene expression (Rab27a, Rab7a, SNAP23, Rab5, ATG5, and ATG16L1) in MSC^IPFP with or without wogonin (25 μM) pretreatment, measured by quantitative real-time polymerase chain reaction (qRT-PCR).
J Cell Mol Med

Jinbei Decoction Attenuates LPS-Induced Acute Lung Injury via Suppression of TRAF6-Dependent Inflammatory Response in Macrophage. [Abstract]

2025 Nov;29(21):e70944. PMID: 41230791
J Cell Mol Med

Wogonin alleviates liver injury in sepsis through Nrf2-mediated NF-κB signalling suppression. [Abstract]

2021 Jun;25(12):5782-5798. PMID: 33982381
Transl Stroke Res

Wogonin Accelerates Hematoma Clearance and Improves Neurological Outcome via the PPAR-γ Pathway After Intracerebral Hemorrhage. [Abstract]

2021 Aug;12(4):660-675. PMID: 32918259
Curr Issues Mol Biol

Deciphering the Mechanism of Wogonin, a Natural Flavonoid, on the Proliferation of Pulmonary Arterial Smooth Muscle Cells by Integrating Network Pharmacology and In Vitro Validation. [Abstract]

2023 Jan 8;45(1):555-570. PMID: 36661523
Toxicol Appl Pharmacol

Wogonin induces mitochondrial apoptosis and synergizes with venetoclax in diffuse large B-cell lymphoma. [Abstract]

2024 Sep 13:117103. PMID: 39278550
Arch Biochem Biophys

Wogonin inhibits the migration and invasion of fibroblast-like synoviocytes by targeting PI3K/AKT/NF-κB pathway in rheumatoid arthritis. [Abstract]

2024 May:755:109965. PMID: 38552763
Exp Cell Res

Network-based analysis with primary cells reveals drug response landscape of acute myeloid leukemia. [Abstract]

2020 Aug 1;393(1):112054. PMID: 32376287
J Immunol Res

Wogonin Suppresses IL-10 Production in B Cells via STAT3 and ERK Signaling Pathway. [Abstract]

2020 Jun 1;2020:3032425. PMID: 32566686

Wogonin purchased from MedChemExpress. Usage Cited in: J Immunol Res. 2020 Jun 1;2020:3032425. [Abstract]

Dose-dependent inhibition of STAT3 and ERK phosphorylation by Wogonin in LPS-treated B cells. CD19⁺ B cells were cultured with LPS for 6 h in the presence or absence of Wogonin (12.5, 25, and 50 μM) are analyzed and quantified by Western Blot.
PeerJ

Regulatory mechanism of Scutellaria baicalensis Georgi on bone cancer pain based on network pharmacology and experimental verification. [Abstract]

2022 Nov 17:10:e14394. PMID: 36415861
Exp Ther Med

Wogonin as a potential therapeutic agent for psoriasis: Core target identification and validation. [Abstract]

2026 Feb 4;31(4):98. PMID: 41694114
In Vitro Cell Dev Biol Anim

Wogonin improves high glucose-induced ARPE-19 cell damage by inhibiting ferroptosis via suppressing the cGAS-STING pathway. [Abstract]

2025 Oct 2. PMID: 41037250
Xenobiotica

Wogonin glucuronidation in liver and intestinal microsomes of humans, monkeys, dogs, rats, and mice. [Abstract]

2020 Aug;50(8):906-912. PMID: 32005083
Oxid Med Cell Longev

Wogonin Strengthens the Therapeutic Effects of Mesenchymal Stem Cells in DSS-Induced Colitis via Promoting IL-10 Production. [Abstract]

2021 Jun 17:2021:5527935. PMID: 34239686

Solvente y solubilidad

In Vitro:

DMSO : 62.5 mg/mL (219.87 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.5179 mL

17.5895 mL

35.1791 mL

5 mM

0.7036 mL

3.5179 mL

7.0358 mL

10 mM

0.3518 mL

1.7590 mL

3.5179 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Calculadora de molaridad

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculadora de dilución

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: 2.08 mg/mL (7.32 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 0.5% CMC-Na/saline water

Solubility: 24 mg/mL (84.43 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocolo

Cell Assay^[1]

HCT116 cells are planted on a 96-well plate (1 × 10⁵ cells per well). Different concentrations of wogonin are added and incubated for 24 h. Subsequently, 20 μL of MTT solution (5 mg/mL) is transferred to each well and the plates are incubated for 4 h at 37°C and 5% CO₂. The supernatant is aspirated off and 100 μL DMSO is added to dissolve the formazan crystal. The mixture is shaken and measured at 570 nm using a universal microplate reader.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[3]

C57BL/6 mice, male, 6-8 weeks old, weighing 18-22 g mice are housed at comfortable environment and are acclimatized for 3 days before the experiment. A total of 48 mice are randomLy divided into six groups of 8 animals, respectively control diet (CD)-fed mice, EtOH-fed mice, wogonin-treated mice at the dose of 25, 50, 100 mg/kg/day and the positive (dexamethasone, 1 mg/kg/day)-treated mice. Modeling process has a total of 16 days including a liquid diet adaptation period for 3 days and modeling for 13 days. The EtOH-fed mice are fed containing 5% v/v ethanol liquid diets adding certain vitamin and choline for 16 days, and mice are gavaged with a single binge ethanol administration (5 g/kg, body weight, 20% ethanol) at last day. At the same time, the wogonin-treated mice and the positive-treated mice are not only plus the ethanol administration, but also plus the medicines by gavage daily, whereas the CD-fed mice are fed with control liquid diets and gavaged with isocaloric maltose-dextrin at last day. All diets are prepared fresh daily. 9 h after the last gavage alcohol, mice are sacrificed under anaesthesia, the liver tissues and blood are collected for further analysis.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Pureza y Documentación

Select Batch:

Pureza: 99.98%

Assay: 99.98%

ee.: 99.98%

Ficha de datos (297 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instrucciones de manejo (2659 KB)

Referencias

[1]. He L, et al. Wogonin induced G1 cell cycle arrest by regulating Wnt/β-catenin signaling pathway and inactivating CDK8 in human colorectal cancer carcinoma cells. Toxicology. 2013 Oct 4;312:36-47. [Content Brief]

[2]. Yang L, et al. Wogonin induces G1 phase arrest through inhibiting Cdk4 and cyclin D1 concomitant with an elevation in p21Cip1 in human cervical carcinoma HeLa cells. Biochem Cell Biol. 2009 Dec;87(6):933-42. [Content Brief]

[3]. Li HD, et al. Wogonin attenuates inflammation by activating PPAR-γ in alcoholic liver disease. Int Immunopharmacol. 2017 Sep;50:95-106. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.5179 mL	17.5895 mL	35.1791 mL	87.9477 mL
	5 mM	0.7036 mL	3.5179 mL	7.0358 mL	17.5895 mL
	10 mM	0.3518 mL	1.7590 mL	3.5179 mL	8.7948 mL
	15 mM	0.2345 mL	1.1726 mL	2.3453 mL	5.8632 mL
	20 mM	0.1759 mL	0.8795 mL	1.7590 mL	4.3974 mL
	25 mM	0.1407 mL	0.7036 mL	1.4072 mL	3.5179 mL
	30 mM	0.1173 mL	0.5863 mL	1.1726 mL	2.9316 mL
	40 mM	0.0879 mL	0.4397 mL	0.8795 mL	2.1987 mL
	50 mM	0.0704 mL	0.3518 mL	0.7036 mL	1.7590 mL
	60 mM	0.0586 mL	0.2932 mL	0.5863 mL	1.4658 mL
	80 mM	0.0440 mL	0.2199 mL	0.4397 mL	1.0993 mL
	100 mM	0.0352 mL	0.1759 mL	0.3518 mL	0.8795 mL

Keywords

Wogonin

25 Cited Publications

100 mg Obtener un presupuesto

Subscribe to the

MedChemExpress

Newsletter

Nombre del producto:
Referencia número:
Cantidad:
MCE Japan Authorized Agent:

Nombre del producto:
No. CAS:
Species:
Pureza:
Cantidad:

Wogonin

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

Stem Cell Signaling Compound Library

Wnt/Hedgehog/Notch Compound Library

Natural Product Library

Anti-Cancer Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Differentiation Inducing Compound Library

Medicine Food Homology Compound Library

Phenols Library

Cytoskeleton Compound Library

Traditional Chinese Medicine Active Compound Library

Flavonoids Library

Neuroprotective Compound Library

Anti-Breast Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Anti-Cancer Natural Product Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Antihypertensive Compound Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Extracellular Vesicles (EVs) Compound Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Miao Ethnicity Medicine Compound Library

Tibetan Medicine Compound Library

PBCRBS Traditional Chinese Medicine Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

RO5 Drug-like Natural Product Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Anti-Rheumatic Arthritis Compound Library

Antitussive and Antiasthmatic Traditional Chinese Medicine Active Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Posttranslational Modification Library

Mongolian Medicine Compound Library

High-Efficiency Gene Editing Compound Library

Tonifying Traditional Chinese Medicine Monomer Compound Library

RNA Binding Bioactive Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Wogonin

Ver todos los productos específicos de isoformas CDK

Ver todos los productos específicos de isoformas Wnt

Actividad biológica

Chemical Information

Publications (25)

Solvente y solubilidad

Protocolo

Pureza y Documentación

Referencias

Help & FAQs

Complete Stock Solution Preparation Table

Wogonin Related Classifications

HY-N0400 Related Classifications